Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Update: Nirsevimab (Beyfortus) – FAQs for Healthcare Professionals
This update from the Pediatric Pandemic Network (PPN) describes the new guidelines from the CDC with additional recommendations from the FDA, AAP, and AAFP. There …
Ask aRCie
Elucidating the Outpatient Burden of RSV Disease in Children
This commentary refers to an article titled "Burden of RSV Infections Among Young Children in Primary Care: A Prospective Cohort Study in Five European Countries …
Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness
2024
· University of Michigan,
· Centers for Disease Control and Prevention (CDC),
· U.S. Public Health Service
This study evaluates the benefits and cost-effectiveness of a vaccine for pregnant women to protect babies from RSV, a virus that can cause serious illness …
RSV Prevention in Infants: Promising Products, But at What Cost?
This commentary is related to two studies on the cost-effectiveness of maternal vaccination and nirsevimab for infants for the prevention of respiratory syncytial virus (RSV). …
The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis
This article discusses the significant burden of respiratory syncytial virus (RSV) in infants in the United States. It covers the epidemiology, hospitalization rates, mortality, costs, …
RSV Prevention Options for Infants and Older Adults: A Specific Expanding Competitive Arena
This article focuses on respiratory syncytial virus (RSV), a common virus that can be serious for infants and older adults. It describes new ways to …
Nirsevimab: The Hidden Costs
This brief article describes how nirsevimab is effective but expensive and raises concerns about its cost-effectiveness. The drug's immunity fades quickly, protecting infants for only …